News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Alper Topal: The Keynote 921 study failed for CRPC
Alper Topal/researchgate.net
Mar 18, 2025, 12:35

Alper Topal: The Keynote 921 study failed for CRPC

Alper Topal, Medical Onoclogist at Gülhane Training and Research Hospital, shared a paper Daniel P. Petrylak and colleagues authored on X:

“The Keynote 921 study failed for CRPC.

mPFS was 8.6 months in the pembro arm compared to 8.3 months in the placebo arm.mOS was 19.6 months in the pembro arm compared to 19 months in the placebo arm. Grade 3≥side effects were more common in the pembro arm.”

Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial

Authors: Daniel P. Petrylak et al.

Alper Topal

Alper Topal Andrew J. Armstrong Andries M. Bergman cancer Charles Schloss Christian H. Poehlein Daniel P. Petrylak Eric Levesque Ernesto Korbenfeld Gero Kramer Howard Gurney Karim Fizazi Loic Mourey Margitta Retz Maria De Santis Meital Levartovsky Nobuaki Matsubara OncoDaily Oncology Pawel Zalewski Raffaele Ratta Ray Manneh Ray McDermott Russell Pachynski Rustem Gafanov Seok Soo Byun Sergio Bracarda Tilman Todenhofer Winald Gerritsen Xin Tong Li
Special Coverage
Blog
Jun 29, 2025, 09:09
Sahar Mansour Supports FUJIFILM Healthcare Middle East and Africa at Africa Health ExCon Conference 2025
Blog
Jun 29, 2025, 09:08
The PEACE-V STORM Trial Final Results Were Presented at ESTRO 2025
Blog
Jun 29, 2025, 09:07
Andreas Charalambous: Great to Meet with Lawson Eng at the MASCC2025
Blog
Jun 29, 2025, 09:00
Wafik El-Deiry Welcomes Dr. Sherise Chantell Rogers as Interim Associate Director for COE at Legorreta Cancer Center
Blog
Jun 29, 2025, 08:58
Toufic Kachaamy: What If You Want More Than What the Cancer Screening Guidelines Offer?
Insight
Jun 29, 2025, 08:11
Elena J. Ladas: Delighted to Share the Release of the IIPAN Manuals for the Delivery of Nutrition Care in LMICs
Blog
Jun 29, 2025, 07:54
Frank Sinicrope: FOLFOX + Atezolizumab is Now Incorporated Into The NCCN Guidelines for dMMR Colon Cancer
Science
Jun 29, 2025, 07:45
Yan Leyfman: Can a Digital Integrative Medicine Program Reduce Cancer-Related Fatigue?
Blog
Jun 29, 2025, 07:39
Raul Cordoba Highlights Study on Performance of CHA2DS2-VASc and HAS-BLED in Predicting Stroke and Bleeding in Atrial Fibrillation and Cancer
Blog
Jun 29, 2025, 07:39
MASCC Highlights Day 1 of MASCC25 in Seattle with Awards and Plenary on Financial Toxicity
Blog
Jun 29, 2025, 07:30
Jame Abraham Congratulates Dr. Brian Murphy on Retirement from Cleveland Clinic Cancer Center
Blog
Jun 29, 2025, 07:26
Emre Yekedüz: A Meta-Analysis From The DADSPORT Collaboration For Nonmetastatic Prostate Cancer